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Abstract 
We investigated a collection of sixty-five strains belonging to the Acinetobacter 
calcoaceticus-Acinetobacter baumannii (ACB) complex obtained from a veterinary clinic. 
Strains originated from animals treated at a veterinary clinic and from the hospital 
environment and had been collected between 2006 and 2017. Assignment to sequence types 
(ST) and international complexes (IC) was done by multilocus sequence typing (MLST). 
Different Genes encoding for antibiotic resistance and virulence were identified by 
microarray. Genes encoding blaOXA-51-like carbapenemases were amplified by PCR and 
sequenced. Susceptibility profiles were determined by disc diffusion or by broth 
microdilution. Among 50 A. baumannii isolates from animals, two predominant clones were 
observed linked to CC1 (n=27 /54% of the isolates) and CC25 (n=14/28%), respectively. Six 
(12%) isolates belonged to CC2, one isolate to CC10 and one to CC149. The remaining 
isolate was assigned to ST1220. Of six environmental A. baumannii, four (66.7%) belonged 
to CC25, one (16.7%) to CC2 and one to CC3. Nine isolates were non-baumannii strains. 
None of the isolates carried blaOXA-23, blaOXA-48, or blaOXA-58, and none were resistant to 
carbapenems. In conclusion, clonal lineages of the veterinary A. baumannii isolates in our 
collection are identical to those globally emerging in humans but do not harbor blaOXA-23. A. 
baumannii CC25 may be specific for this particular veterinary clinic environment. 
 
Keywords: Acinetobacter, blaOXA-51-like, genotypes, antimicrobial resistance, animals 
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Zusammenfassung 
Es wurde ein Kollektiv von 65 Stämmen untersucht, die zum Acinetobacter calcoaceticus-
Acinetobacter baumannii (ACB) Komplex gehören. Die Isolate stammen aus den Jahren 2006 
bis 2017 und wurden aus Tieren, die in einer Klinik behandelt wurden und aus der 
Klinikumgebung isoliert. Der Sequenztyp (ST) und die clonalen Komplexe (CC) wurden 
mittels multilocus Sequenz Typisierung (MLST) ermittelt. Verschiedene Gene für 
Antibiotikaresistenzen und Virulenzfaktoren wurden mit Microarray nachgewiesen. Die 
Empfindlichkeit gegen verschiedene Antibiotika, wurde mit der Disc Diffusion Methode oder 
mit Microdilution getestet. Bei den 50 A. baumannii Isolaten von Tieren, kamen zwei 
dominierende Klone vor, welche zu den CC1 (n=27/54%) und CC25 (n=14/28%) zählen. 
Sechs (12%) Isolate gehören zu CC2, ein Isolat zu CC10, eines zu CC149 und eines ist dem 
ST1220 zuzuordnen. Von den sechs A. baumannii aus der Klinikumgebung, gehörten vier 
(66.7%) zu CC25, einer (16.7%) zu CC2 und einer zu CC3. Es wurden neun nicht-baumannii 
Stämme gefunden. Bei keinem Stamm wurde ein blaOXA-23, blaOXA-48, oder blaOXA-58 
nachgewiesen und es wurde kein Carbapenem resistenter Stamm gefunden. Abschliessend 
lässt sich sagen, dass die untersuchten A. baumannii Stämme clonale Komplexe aufweisen, 
die weltweit auch bei Isolaten von Menschen gefunden werden. Jedoch besass kein Stamm 
dieser Studie ein blaOXA-23. A. baumannii CC25 scheint spezifisch für die in dieser Studie 
untersuchte Tierklinik zu sein. 
 
Schlüsselwörter: Acinetobacter, blaOXA-51-like, Genotypen, Antibiotikaresistenz, Tiere 
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Abstract 
Objectives: We investigated a collection of strains belonging to the Acinetobacter 
calcoaceticus-Acinetobacter baumannii (ACB) complex obtained from a veterinary clinic 
with regard to their genetic relatedness, presence of antibiotic resistance genes and 
antimicrobial susceptibility profiles. 
Methods: Fifty-eight ACB-complex strains from animals treated at a veterinary clinic 
between 2006 and 2017, and seven strains collected from the hospital environment during 
2012 were analysed. Assignment to sequence types (ST) and international complexes (IC) 
was done by multilocus sequence typing (MLST) according to the Pasteur scheme. Genes 
encoding carbapenemases, aminoglycoside-modifying enzymes, macrolide-, quinolone- and 
co-trimoxazole resistance genes, the ISAba1 element, virulence associated intI1 genes and 
plasmid associated toxin-antitoxin markers were identified by microarray. Genes encoding 
blaOXA-51-like carbapenemases were amplified by PCR and sequenced. Susceptibility profiles 
were determined by disc diffusion or by broth microdilution.  
Results: Among 50 A. baumannii isolates from animals, two predominant clones were 
observed linked to CC1 (n=27 /54% of the isolates) and CC25 (n=14/28%), respectively. 
Strains of IC I harbored blaOXA-69, aac(3')-la, aadA1, sul1, intI1, and splA/T genes. Isolates 
belonging to CC25 possessed blaOXA-64. Six (12%) isolates belonging to CC2 and carrying 
blaOXA-66 were also noted. One isolate belonged to CC10 (blaOXA-68), one to CC149 (blaOXA-
104), the remaining isolate was assigned to ST1220 and possessed blaOXA-116. Of six 
environmental A. baumannii, four (66.7%) belonged to CC25 (blaOXA-64), one (16.7%) to CC2 
(blaOXA-66) and one to CC3 (blaOXA-71). 
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Nine isolates (eight from animals and one environmental strain) were non-baumannii strains 
and did not harbor blaOXA-51-like genes. None of the isolates carried blaOXA-23, blaOXA-48, or 
blaOXA-58, and none were resistant to carbapenems.  
Conclusions: Clonal lineages of the veterinary A. baumannii isolates in our collection are 
identical to those globally emerging in humans but do not harbor blaOXA-23. A. baumannii 
CC25 may be specific for this particular veterinary clinic environment. 
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Introduction 
The genus Acinetobacter is ubiquitous in diverse environments and as of today comprises 60 
validly published species names (www.szu.cz/anemec/Classification.pdf). A list of 
Acinetobacter spp. also available at  http://www.bacterio.net (Parte, 2018). In clinical settings, 
the species belonging to the Acinetobacter calcoaceticus- Acinetobacter baumannii (ACB) 
complex are of greatest importance (Towner, 2009). The ACB complex currently comprises 
Acinetobacter baumannii and its close relatives, A. calcoaceticus, A. dijkshoorniae (Cosgaya 
et al., 2016), A. lactucae (Rooney et al., 2016), A. nosocomialis,  A. pittii, (Nemec et al., 
2011), and A. seifertii (Nemec et al., 2015). Currently, A. dijkshoorniae  and A. lactucae are 
considered conspecific (Dunlap and Rooney, 2017). Hence, there exist to date six distinct 
ACB complex species with formal nomenclatural recognition. 
A. baumannii is the most frequent Acinetobacter species isolated from patients in intensive 
care units (ICUs) and is the causative agent of ventilator associated pneumonia, catheter-
related bloodstream infections, meningitis, and wound infection, often causing clonal 
outbreaks involving critically ill patients (Fitzpatrick et al., 2015; Higgins et al., 2010). By 
constrast, A. calcoaceticus, although found sometimes in clinical specimens, seems to be 
more environmental, has unknown clinical significance and is usually well-susceptible to 
antibiotics (Doi et al., 2015). 
The diversity of strains in epidemiology studies of A. baumannii is frequently investigated by 
multilocus sequence typing (MLST) using either the Oxford or the Pasteur scheme (Bartual et 
al., 2005; Diancourt et al., 2010). The majority of outbreak strains reported globally belong to 
IC I, IC II and IC III, corresponding to clonal complexes (CC)1, CC2 and CC3 of the Pasteur 
scheme (Tomaschek et al., 2016; Diancourt et al., 2010; Higgins et al., 2010; Zarrilli et al., 
2013). 
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Treatment of infections is frequently compromised due to the fact that ACB complex strains 
possess multiple intrinsic and acquired mechanisms that may result in antimicrobial resistance 
(van der Kolk et al., 2018; Doi et al., 2015). Overexpression of intrinsic ß-lactamases and of 
multidrug resistance efflux pumps, loss of outer membrane proteins and mutations in the 
quinolone resistance-determining regions (QRDRs) of the gyrA and parC are commonly 
detected in ACB isolates (Doi et al., 2015). Hence, following CLSI guidelines, ACB isolates 
are considered intrinsically resistant to antibiotics such as aminopenicillins, aztreonam, 
ertapenem, trimethoprim, chloramphenicol, macrolides and fosfomycin (CLSI, 2017).  
Importantly, in addition to the presence of chromosomally located blaOXA-51-like genes 
encoding for naturally occurring carbapenemases, plasmid mediated carbapenem resistance 
genes including blaOXA-23, blaOXA-48, and blaOXA-58 have emerged globally in A. baumannii 
further restricting therapeutic options for treating infections in humans, with blaOXA-23 
harboring A. baumannii representing one of the most problematic hospital-acquired human 
pathogens (Mugnier et al., 2009). 
Data on molecular characteristics and antimicrobial resistance mechanisms of Acinetobacter 
of veterinary origin are still scarce compared to those of isolates from humans. However, it 
has been shown that A. baumannii isolated from animals may share clonal lineages and 
possess identical transmissible antibiotic resistance genes to those from humans, suggesting 
common pathways and/or sources of infection (van der Kolk et al., 2018; Zordan et al., 2011). 
Furthermore, reports on the emergence of infections due to carbapenem resistant A. 
baumannii in hospitalized companion animals are of concern and emphasize the need for 
epidemiological studies and surveillance in order to maintain veterinary and public health 
(Ewers et al., 2017; Lupo et al., 2017; Hérivaux et al., 2016; Pomba et al., 2014).   
The present study was designed to characterize clinical isolates belonging to the ACB 
complex originating from companion animals and horses hospitalized during 2006–2017 at a 
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university veterinary clinic in Switzerland by (i) determining the genetic relatedness using 
multilocus sequence typing, (ii) performing genetic profiling using a microarray-based assay, 
and (iii) assessing their antimicrobial susceptibility profiles. 
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Materials and methods 
Bacterial isolates 
Between 2006 and 2017, a total of 93 non-duplicate Acinetobacter spp. isolated from 
hospitalized animals (one strain per animal) were obtained. Only isolates with clinical 
significance were collected. In addition, strains taken from the hospital environment during 
2012 (n=7) were included in the study. Strains were identified to the level of the genus 
Acinetobacter using the VITEK® 2 Compact system (Biomérieux, Nürtingen, Germany).  
Species identification was performed by matrix-assisted laser desorption/ionization time-of- 
flight mass spectrometry (MALDI-TOF–MS, Bruker Daltronics, Bremen, Germany) and by 
amplification and sequencing of the 350 bp highly variable zone 1 of the rpoB gene (Gundi et 
al., 2009; La Scola et al., 2006). Custom sequencing was done by Microsynth, Balgach, 
Switzerland.  
In total, 65 ACB complex strains were identified, including 56 A. baumannii (50 isolates from 
animals, and six environmental strains), seven A. pittii (six animal, and one environmental 
isolate), and two animal A. calcoaceticus isolates. 
The 58 animal strains originated from horses (n=35), cats (n=7), dogs (n=6), chicken (n=3), 
rabbits (n=2), Andean bear (n=1), cattle (n=1), donkey (n=1) reptile (n=1), and rodent (n=1) 
admitted to the veterinary clinic of the University of Zürich, Switzerland. The isolates were 
cultured from wounds (n=20), abscesses (n=19), urine (n=4), synovial fluid aspirations (n=2), 
tracheobronchial secretions (n=2), abdominal aspiration (n=1), alveolus (n=1), bladder wall 
(n=1), eye swab (n=1), implant (n=1), pus (n=1), surgical sites (3), and other sites (n=2).  
In addition, strains collected from the hospital environment during 2012 (n=7) were included 
in the study. 
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Non-ACB-complex strains (n=35) comprising 21 A. lwoffii/‘A. pseudolwoffii’ (Nemec et al., 
2018), three A. guillouiae, three A. radioresistens, two A. beijerinckii, two A. towneri, one A. 
gandensis, one A. junii, one A. parvus, and one A. ursingii were not included in this study. 
In accordance with local legislation, ethics approval was not required and no animal 
experiments were carried out for this study. 
 
Multilocus sequence typing 
Multilocus sequence typing was performed according to the scheme developed by the Pasteur 
Institute (Diancourt et al., 2010). This scheme involves PCR amplification and sequencing of 
internal fragments of seven housekeeping genes (fusA, gltA, pyrG, recA, cpn60, rpoB, and 
rplB). Primers and PCR conditions are listed at the A. baumannii MLST database website 
http://pubmlst.org/abaumannii/. Sequencing of the amplification products was performed by 
Microsynth (Balgach, Switzerland). Sequences were uploaded to 
http://pubmlst.org/abaumannii/ to identify alleles and sequence types. The population 
structure of STs of the A. baumannii isolates was evaluated using the goeBURST software 
(http://www.phyloviz.net/goeburst/). CCs were defined as single-locus (SLVs) and double-
locus variants (DLVs). 
 
Identification of antimicrobial resistance genotypes 
DNA was purified using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany), 
according to manufacturer’s protocol. 
Isolates were genotyped using the oligonucleotide based microarray CarbDetect AS-2 Kit 
(Alere Technologies GmbH, Jena, Germany) to detect all currently known relevant 
carbapenemase genes, extended-spectrum ß-lactamase (ESBL) genes, aminoglycoside, 
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macrolide, quinolone and co-trimoxazole resistance genes found in Enterobacteriaceae and 
Pseudomonadales (Braun et al., 2014). Additional markers included the ISAba1 element, 
integrase and transposase genes, and plasmid associated toxin-antitoxin (T/A) markers. An 
overview of the target genes and multiplex labelling, hybridization and data analysis has been 
described by Braun et al. (2014).  In brief, DNA was labelled internally with biotin-11-dUTP 
using a linear amplification protocol to generate single stranded (ss) DNA. Biotin labelled 
ssDNA was transferred and hybridized with DNA probes in oligonucleotide microarray strips. 
Hybridization was detected using streptavidin-horseradish peroxidase and a dye precipitation. 
The signals were detected using the platform ArrayMate Reader provided by Alere 
Technologies GmbH. 
PCR and DNA sequencing analyses of blaOXA-51-like genes in A. baumannii isolates was 
carried out using custom synthesized primers (Microsynth, Balgach, Switzerland) and 
conditions published previously (Pournaras et al., 2014). Nucleotide sequences were analyzed 
with the CLC Main Workbench 8.0.1 and the BLASTN program of NCBI 
(http://www.ncbi.nlm.nih.gov/blast/). 
Screening for the plasmid-mediated colistin resistance genes mcr-1, mcr-2, mcr-3, mcr-4 and 
mcr-5 was performed by PCR using custom synthesized primers (Microsynth, Balgach, 
Switzerland) and conditions described previously (Rebelo et al., 2018).  
The mcr-1 harboring strain OW3E1 (Zurfluh et al., 2016) and plasmid “Plasmid-MCR2-
Positivkontrolle” (P. Keller, personal communication) were used as positive controls. 
 
Phenotypical characterization of antibiotic susceptibility 
Antimicrobial susceptibility testing was carried out according to Clinical and Laboratory 
Standards Institute (CLSI) performance standards (CLSI., 2017), using the disk-diffusion 
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method and the antibiotics cefotaxime (CTX), cefepime (FEP), ciprofloxacin (CIP), 
sulfamethoxazole/trimethoprim (SXT), gentamicin (GM), and tetracycline (TE). Minimal 
inhibitory concentrations (MIC) of imipenem were determined using the E-Test® 
(bioMérieux, Marcy L’Etoile, France) according to manufacturer’s protocol.  Determination 
of the MIC of colistin was performed by broth microdilution according to the European 
Committee on Antimicrobial Susceptibility Testing EUCAST (eucast.org). 
The degrees of antimicrobial resistance among the ACB complex isolates was defined in 
accordance to Falagas and Karageorgopoulos (2008). 
Multidrug resistance (MDR) was thereby defined as resistance to three or more classes of 
antimicrobial agents including β-lactams, fluoroquinolones, sulfonamides, aminoglycosides, 
tetracyclines, and polymyxins, and excluding those which cannot be regarded as potentially 
effective, i.e., to which ACB complex strains are intrinsically resistant: aminopenicillins, 
aztreonam, ertapenem, trimethoprim, chloramphenicol, macrolides and fosfomycin (CLSI, 
2017). 
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Results 
An overview of the isolates, their origins, molecular and phenotypic characteristics is shown 
in Figure 1.  
Overall, 58 clinical isolates belonging to the ACB complex were collected from animals 
admitted to the veterinary hospital of Zürich, Switzerland between 2006 and 2017. The 
majority thereof (50/86.2%) were A. baumannii isolates collected from horses (n=34), dogs 
(n=6), cats (n=5), rabbits (n=2), and from one chicken, one donkey and one reptile, 
respectively. Six (10.3%) of the clinical isolates were A. pittii collected from cats (n=2), 
chicken (n=2), and from one Andean bear and one rodent, respectively. Two isolates (3.4%) 
were A. calcoaceticus from a cow and from a horse, respectively. 
Environmental isolates collected from the premises of the veterinary hospital during 2012 
included six A. baumannii and one A. pittii (Figure 1). 
Multilocus sequence typing revealed that the majority (27/48.2%) of the 56 A. baumannii 
isolates belonged to ST20 and its SLVs ST1, ST1217, and ST1219, as well as its DLV 
ST1214. eBurst analysis assigned these sequence types to clonal complex CC1 (Figure 2). 
Fourteen (25%) of the A. baumannii strains belonged to ST25 and its SLV ST1218 and were 
assigned to CC25. Of the remaining isolates, six (10.7%) belonged to ST2 (CC2), and one 
(1.8%) to ST23 (CC10) and one to ST46 (CC149). One isolate typed and ST1220 and was not 
assigned to any CC (Figure 2).  
Microarray based genotyping revealed the presence of blaOXA-51-like genes in all A. 
baumannii isolates. None of the A. pittii or A. calcoaceticus isolates tested positive for blaOXA-
51-like genes (Figure 1).  
Sequencing analysis of the blaOXA-51-like genes revealed the presence of blaOXA-69 in all 27 A. 
baumannii belonging to CC1 (Figure 1 and Figure 2). The blaOXA-64 gene was detected in the 
18 A. baumannii isolates belonging to CC25, and blaOXA-66 was identified in the seven strains 
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belonging to CC2. Other alleles included blaOXA-71, blaOXA-104, and blaOXA-116 (Figure 1 and 
Figure 2). 
The ß-lactamase genes blaTEM and blaACT were found in 44 and 2 of the isolates, respectively 
(Figure 1). 
Other bla genes encoding for carbapenemases (e.g. OXA-23, OXA-48, OXA-58, KPC or 
NDM), or for acquired ESBLs (e.g. PER, VEB or CTX-M types) were not detected. 
The ISAba1 element which accounts for enhanced expression of blaOXA-51-like genes was 
detected adjacent to blaOXA-66 in two of the isolates (MAC5 and MAC22, Figure 1). In one 
isolate (MAC-52) the element was not associated with blaOXA-66 (Figure 1). 
Genes associated with resistance to aminoglycosides, macrolides, sulphonamides and 
trimethoprim were detected as shown in Figure 1. The aac(3’)-Ia, aadA1, aphA, and sul1 
genes occurred predominantly in association with the presence of the class 1 integrase gene 
intI1 in A. baumannii belonging to CC1 and CC2, whereas the majority of strains that lacked 
the intI1 gene harbored strA and/or strB and sul2 (Figure 1). 
The type II T/A genes splA and splT were identified in all A. baumannii belonging to CC1.  
In one strain (MAC-32), the toxin-antitoxin system was incomplete (Figure 1).  
None of the isolates tested positive for mcr genes. 
The antimicrobial susceptibility profiles of the isolates are summarized in Figure 1. The 
majority (52/92.9%) of the 56 A. baumannii strains was resistant to three or more classes of 
antimicrobials and were MDR according to Falagas and Karageorgopoulos (2008) . By 
contrast, among the A. calcoaceticus and A. pittii strains, one isolate (MAC-70) was resistant 
to gentamicin, the rest remained susceptible to all tested antimicrobials, and none were MDR.  
Overall, 51 (91%) of the A. baumannii isolates were resistant to ciprofloxacin and to 
tetracycline, respectively, 47 (83.9%) were resistant to gentamicin, 43 (76.8%) were resistant 
to sulfamethoxazole-trimethoprim, and 10 (17.9%) were resistant to cefotaxime. Two (3.6%) 
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isolates were resistant to colistin. All were susceptible to cefepime and imipenem, with MIC 
of imipenem ranging from 0.125 to 1.5 µg/ml (Figure 1).  
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Discussion 
There is growing concern that multidrug resistant, blaOXA-23 harboring A. baumannii in 
hospitalized companion animals and horses may be emerging as a threat to veterinary and 
public health (van der Kolk et al., 2018). However, information on A. baumannii in veterinary 
medicine is still limited and there is a lack of comparable data to strains isolated from humans 
(van der Kolk et al., 2018; Müller et al., 2014). In this study, we provide a molecular and 
phenotypic analysis of strains belonging to the ACB complex isolated from diseased animals 
admitted to the veterinary hospital of the university of Zürich, Switzerland during 2006–
2017. The main limitations of this study include its retrospective design and its restriction to a 
single center. 
The two predominant lineages of A. baumannii comprised CC1, which is a globally 
distributed clade (Higgins et al., 2010), and CC25, a lineage that has been responsible for 
epidemics in different European countries (Sahl et al., 2015).  
There are few reports on A. baumannii isolated from pets in Switzerland and overall, these 
isolates belonged primarily to CC1and CC2 (Endimiani et al., 2011; Boerlin et al., 2001). 
Likewise, Ewers et al. (Ewers et al., 2017) observed a prevalence of 26% of CC2 among A. 
baumannii recovered from animals hospitalized in various veterinary clinics in Germany, 
which is remarkably higher than the prevalence of 12% observed in this study. By contrast, A. 
baumannii ST25 (CC25) was not described in either of these studies. Its abundance in the 
collection of ACB isolates from the veterinary hospital of Zürich suggests that this clinical 
setting may be likely support the spread of this particular clonal lineage. Moreover, of the six 
environmental A. baumannii recovered during 2012, four (66.7%) belonged to ST25 (CC25), 
suggesting the existence of an environmental reservoir of this ST in or outside of the hospital 
setting. Its prevalence in the hospital environment may also be due to the elevated resistance 
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to desiccation and high biofilm-forming capacity on abiotic surfaces, as demonstrated for this 
particular sequence type (Giannouli et al., 2013). 
Notably, A. baumannii ST25 has recently been isolated from pets in France (Lupo et al., 
2017; Hérivaux et al., 2016). In both studies, the isolates possessed blaOXA-23 and were 
resistant to carbapenems, whereas the isolates analyzed in the current report possessed 
intrinsic blaOXA-51 –like carbapenemases only. Interestingly, the isolates from France were 
detected in companion animals in the community. Compared to clinical settings, little is 
known about Acinetobacter carriage in animals beyond these settings, but several studies 
during the last decade have detected A. baumannii in dogs in the community (Hérivaux et al., 
2016) (Pailhoriès et al., 2015), domestic birds (Klotz et al., 2018), livestock (Poirel et al., 
2012) and other farmed animals such as mink (Molenaar and van Engelen, 2015). These 
reports indicate that community-acquired A. baumannii infections among animals may be 
increasing and that animals outside clinical settings may represent a reservoir for A. 
baumannii, including carbapenem resistant strains (van der Kolk et al., 2018). 
Overall, the blaOXA-51 alleles identified in the A. baumannii isolates correlated with their 
respective CCs, in accordance with previous observations for human isolates (Pournaras et al., 
2014; Evans et al., 2008). 
Two isolates possessed the ISAba1 element upstream of blaOXA-66. As reported earlier, ISAba1 
mediates overexpression of blaOXA-51-like enzymes, resulting in resistance to carbapenems 
(Figueiredo et al., 2009; Turton et al., 2006). However, there was no difference in the MICs of 
imipenem for these two isolates compared to those lacking the ISAba1 insertion, confirming 
recent observations that resistance to carbapenems is not guaranteed only by the presence of 
ISAba1, but depends on its orientation upstream of the bla gene (Nigro and Hall, 2018; 
Rodrigues-Costa et al., 2018). 
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Aminoglycoside resistance genes were distributed unevenly among the A. baumannii isolates. 
The occurrence of aadA1 and aphA in association with intI1among CC1, CC2 and CC3 is 
supportive of previous observations (Nemec et al., 2004). By contrast, these genes were not 
prevalent among the CC25 isolates, among which strA and strB genes predominated. This 
may indicate that interclonal horizontal gene transfer plays a minor role in the dissemination 
of aminoglycoside resistance in the isolates analyzed in this study. 
Of the two colistin resistant isolates, one belonged to CC25, which also occurs in humans. 
Colistin resistance in human Acinetobacter isolates is a source of great concern, although to 
date, there have been no reports of mcr positive Acinetobacter spp. (Rahman et al., 2017).  
In general, there was a good correlation between the presence of resistance genes detected by 
microarray and the phenotype of the isolates. There was however, a discrepancy between 
results of genotypic and phenotypic testing for three of isolates containing sulfonamide 
resistance genes and 4 isolates harboring aminoglycoside resistance genes, where the presence 
of resistance genes did not correspond with phenotypic resistance. Conversely, there was a 
lack of blaESBL genes such as blaGES, blaPER, or blaVEB that would explain the phenotypic 
resistance to cefotaxime observed in 10 isolates (Doi et al., 2015). On the other hand, ISAba1 
and ISAba125 governed hyperexpression of the chromosomal blaADC cephalosporinase also 
leads to resistance to 3rd generation cephalosporins in A. baumannii (Doi et al., 2015; Lopes 
and Amyes, 2012). Thus, further investigations targeting the genetic environment of blaADC in 
the cefotaxime resistant isolates are warranted to explain their phenotype. 
In this study, we observed the presence of type II T/A genes splA and splT in A. baumannii 
CC1. Type II T/A systems are usually plasmid encoded and mediate plasmid maintenance 
through the post-segregational killing of plasmid-free daughter cells (Hayes, 2003). The splA 
and splT genes are so far unique to A. baumannii and are encoded on small, ca. ~10 kb 
plasmids of the Rep-3 superfamily (Lean and Yeo, 2017; Jurenaite et al., 2013). There is a 
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lack of knowledge regarding these plasmids, however, some harbor blaOXA-24/blaOXA-40 or 
blaOXA-72 and are prevalent among carbapenem-resistant human clinical IC II isolates in 
Eastern Europe (Lean and Yeo, 2017). The significance of the splA/T carrying plasmids 
identified among the CC1 isolates in this study remains to be investigated. 
Finally, non-baumannii ACB complex species accounted for 13.8% of the animal, and 14.3% 
of the environmental isolates. These isolates were distinguished from A. baumannii strains by 
the lack of blaOXA-51-like genes, the low prevalence of acquired antibiotic resistance genes and 
high rate of susceptibility to antimicrobial agents, in agreement with observations from 
human isolates (Chen et al., 2018; Fitzpatrick et al., 2015).  
In conclusion, this study provides a molecular and phenotypic analysis of ACB complex 
isolates obtained from animals admitted to a veterinary hospital in Switzerland during 2006-
2017. Using established methods applied to isolates of human origin enabled the 
identification of clonal lineages and resistance determinants that occur globally among human 
isolates, including CC1 and CC25 A. baumannii. As opposed to A. baumannii CC1, CC25 
isolates have infrequently been described in companion animals, but were prevalent among 
the isolates in this study. Contrasting to frequently occurring human clinical isolates 
worldwide, the veterinary ACB complex isolates in this study did not possess any known 
acquired carbapenemase genes. However, since A. baumannii, including CC25 isolates are 
emerging as blaOXA-23 carrying veterinary isolates in other countries, increased surveillance 
and targeted measures to prevent the dissemination of ACB complex strains are warranted. 
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Figure 1: Molecular and phenotypic characterization of strains belonging to the 
Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex isolated from animals 
and the environment at a veterinary hospital in Switzerland, 2006-2017. 
AA, abdominal aspiration; ABS, abscess; ALV, alveolus; AZM, azithromycin; BW, bladder 
wall; CC, clonal complex; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; DO, door; 
ES, eye swab; ENV, environment; FEP, cefepime; FL, floor; GM, gentamicin; IM, implant; 
IP, imipenem; MIC, minimal inhibitory concentration; MDR, multidrug resistant; SS, 
surgical site; SFA, synovial fluid aspiration; ST, sequence type; SXT, 
sulfamethoxazole/trimethoprim; TBS, tracheobronchial secretion; TE, tetracycline; UR, 
urine; WA, water; WP, water pipe; WO, wound. 
* in isolate MAC-52, the ISAba1 element was not associated with blaOXA-66. 
Blue squares, positive result; red squares, resistant to a specific antimicrobial; grey squares, 
intermediately resistant to a specific antimicrobial; light grey squares, negative result or 
susceptible to a specific antimicrobial; purple squares, multidrug resistant.  
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Figure 2: Genetic relatedness of Acinetobacter baumannii isolated from animals and the 
environment at a veterinary hospital in Switzerland during 2006–2017 using multilocus 
sequence typing (MLST) and goeBurst (Phylowiz). 
The sizes of the squares reflect the number of strains belonging to a particular sequence type 
(ST). Blue links show single locus variants (SLVs). Founder STs are highlighted in yellow. 
Green circles indicate isolates grouped into a clonal complex (CC) harboring a particular 
blaOXA-51-like allele. 
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